A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

NCT06892288 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Phosphomannomutase 2 Deficiency
PMM2-CDG

Interventions

DRUG: GLM101 (Part A, Double-blind)
DRUG: Placebo (Part A, Double-blind)
DRUG: GLM101 (Part B, Open-label)

Sponsor

Glycomine, Inc.